Socioeconomic status (SES) is an important determinant of disparities in health care. The association of SES with outcomes in autologous hematopoietic cell transplantation (AHCT) has not been described previously. We conducted a retrospective cohort study of 687 AHCT recipients with lymphoma transplanted between 2003 and 2013. Patients were categorized into low (o$50 000/year) and high SES (⩾ $50 000/year). A greater proportion of low SES patients lived farther away from our center (median 54 vs 28 miles), belonged to a racial minority (12 vs 3%), had poorer performance status (4 vs 1%) and had high-risk disease at AHCT (9 vs 5%). Median follow-up was 53 months. In univariable analysis, low SES patients had significantly higher relapse mortality and lower OS and PFS. This was confirmed on multivariable analysis for relapse mortality (HR for high vs low SES: 0.74 (95% confidence interval (CI), 0.54-0.99), P = 0.05), OS (HR 0.74 (0.58-0.95), P = 0.02) and PFS , P = 0.02). In multivariable analysis of ⩾1-year progression-free survivors, high SES patients had better OS (HR 0.73, P = 0.05 vs low SES) that was primarily driven by a trend toward lower risk of non-relapse mortality (HR 0.62, P = 0.06). SES is associated with outcomes of AHCT in patients with lymphoma.
INTRODUCTION
Disparities in health care are a complex and important determinant of access to treatment and outcomes in cancer patients. Although race and gender are among the most frequently studied social factors in cancer outcomes, other factors have been found to be relevant as well. [1] [2] [3] [4] These factors include SES, 1, 5 access to and type of health insurance, 3, 6 distance to the health-care facility, 2,7-9 cultural factors and health literacy. 10 Among all parameters that represent health-care disparities, socioeconomic status (SES) is a major determinant of economic resources and has been shown to greatly impact health outcomes. 1, 11 Hematopoietic cell transplantation (HCT) is a complex, highly-specialized and resource-intensive procedure that is available at selected centers in the country, and hence may be especially prone to health-care disparities. 12 The association of sociodemographic factors with access and outcomes has been reported in allogeneic HCT; 12, 13 African-Americans are less likely to receive allogeneic HCT for leukemia and lymphoma. 14, 15 African-American patients and patients from low SES have been shown to have inferior OS and higher non-relapse mortality (NRM) compared with allogeneic HCT recipients who are White or come from a high SES background. 13 Health-care disparities have been less well described in autologous hematopoietic cell transplantation (AHCT) recipients. A study on patients with multiple myeloma showed that utilization of AHCT was less for those from low SES. 5 One previous study showed no difference in survival between Black and White patients in AHCT for myeloma. 16 However, due to the lack of data, this study could not evaluate SES or other sociodemographic factors. 16 The association of SES with outcomes in lymphoma patients undergoing AHCT has not been reported previously. We conducted a single institution retrospective cohort study to address this question.
MATERIALS AND METHODS
Using our institutional BMT database, which prospectively collects clinical and outcomes data on all consecutive HCTs, we identified adult patients with lymphoma who received AHCT from 2003 to 2013. Of 696 patients identified, 9 patients were excluded for lack of consent for research (N = 7), history of prior AHCT (N = 1), and home address outside the United States (US) (N = 1). Lymphoma types included Hodgkin lymphoma (N = 154, 22%), diffuse large B-cell lymphoma (N = 262, 38%), follicular lymphoma (N = 102, 15%), mantle cell lymphoma (N = 99, 14%), T-cell lymphoma (N = 52, 8%) and other non-Hodgkin lymphoma (NHL; N = 18, 3%). Disease status was categorized using standard criteria into low-, intermediate-and high-risk disease. 17 Race/ethnicity was self-reported. The study was conducted under the guidance of the Cleveland Clinic Institutional Review Board.
The median annual household income by ZIP Code of primary residence at the time of AHCT estimated by the 2010 United States Census data described SES. 18 Recursive partitioning analysis was used to determine the best cutpoint in median annual household income to predict OS, and was categorized as o$50 000/year (low SES) and ⩾ $50 000/year (high SES). This corresponds to twice the threshold used to define poverty level for a 4-member household in the US. 19 The Cleveland area, where our institution is located, is the largest metropolitan city in the state of Ohio. The median household income for Cleveland (in 2014 dollars) is $26 179, compared with $53 482 for the US.
evidence of disease progression. This is based on an observation made in allogeneic HCT recipients, and corresponds to the transition of patients from transplant centers to community providers and a cohort of patients at high risk for late complications. 22 Patient and disease characteristics were compared by SES using Chi-square or Wilcoxon rank-sum test. OS and PFS were estimated with Kaplan-Meier method and compared with the log-rank test; all other outcomes were estimated with cumulative incidence and compared with the Gray test. Multivariable analyses using Cox Regression or Fine and Gray methods, as appropriate, accounted for the following clinical prognostic factors: distance from our transplant center, age at AHCT, gender, history of prior cancer, prior chemotherapy, prior radiation therapy, time from diagnosis to transplant, disease risk category and lymphoma stage. Analyses were performed using the SAS software (version 9.4, Cary, NC, USA) and all P-values were two sided. P-value ⩽ 0.05 was considered as statistically significant.
RESULTS

Patient characteristics
The study population is summarized in Table 1 . The median annual household income for the low and high SES cohorts was $42 351 and $63 346, respectively. A significantly greater proportion of patients in the low SES cohort lived further away from our transplant center, identified with non-White race/ ethnicity and had poor performance status at AHCT. There were also differences in lymphoma subtypes and disease risk at AHCT. Otherwise, the two cohorts were comparable. The majority of patients (93%) received busulfan, cyclophosphamide and etoposide as conditioning regimen. A small portion (5%) received a planned tandem autologous transplantation on an institutional Hodgkin lymphoma protocol. The median follow-up was Table 1 . Characteristics of all patients and 1-year progression-free survivors by median household income
Characteristics
All patients 1-year progression-free survivors (13) 54 (17) 38 (14) 51 (19) T-cell lymphoma 26 (7) 26 (8) 18 (7) 19 (7 
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49 months (range 7-141 months) for low SES and 58 months (range 3-146 months) for high SES cohorts. Overall, 551 patients were included in the subgroup analysis that included 1-year progression-free survivors. The median annual household income was $42 584 and $64 139 in the low and high SES cohorts, respectively. Like the analysis that included all patients, low SES 1-year progression-free survivors were more likely to live further away from our transplant center and belong to a minority racial group. Similar differences in lymphoma subtypes were also observed.
Transplant outcomes for all patients Five-year OS and PFS were significantly higher in patients from high SES group (Table 2, Figure 1 ). The 5-year cumulative incidence of relapse mortality was also significantly lower in the high SES, and there was a non-significant trend toward a lower incidence of relapse in this population. However, we observed no difference in the cumulative incidence of NRM by SES.
In multivariable analyses, high SES was independently associated with superior OS and PFS (Table 3 ). There was a lower risk of relapse mortality and a non-significant trend toward lower risks of relapse in high SES patients, although there was no difference in the risks of NRM (Table 3) . We did not observe any association between race/ethnicity or distance from our transplant center and outcomes. Older age at AHCT, number of pre-AHCT chemotherapy regimens, disease status and lymphoma subtype were other variables associated with. More pre-AHCT chemotherapy regimens were independent predictor of PFS. Disease status and male gender were associated with higher risks of PFS, relapse and relapse mortality. No patient, disease or transplant-related covariate was associated with NRM. In addition to evaluating SES as a categorical variable, we also considered OS, PFS, relapse, relapse mortality and NRM per $10 000 increase in median household income. Similar results were observed in univariate analyses, including a statistically significant association with OS (HR 0.90, 95% CI 0.84-0.98, P = 0.01) and PFS (HR 0.93, 95% CI 0.87-0.99, P = 0.02).
The causes of death were comparable between the SES groups. The most common causes of death in low and high SES cohorts were relapse (66 vs 66%), organ failure (11 vs 11%), secondary malignancy (9 vs 10%) and infection (4 vs 5%).
Transplant outcomes for 1-year progression-free survivors There was a trend toward higher OS at 5 years in high SES patients that was accompanied by a trend toward lower incidence of NRM (Figure 2) . However, the 5-year rates of PFS, relapse mortality and relapse were comparable (Table 2) .
In multivariable analyses, 1-year AHCT survivors from high SES group had significantly better OS compared with low SES patients and there was a trend toward lower risks of NRM (Table 3) . However, there was no association between SES and PFS, relapse mortality or relapse. Similar to the analysis for the whole cohort, we did not observe any association of race/ethnicity or distance from the transplant center with outcomes. More pre-AHCT chemotherapy regimens were predictive of poorer OS and PFS. Worse disease status was associated with relapse mortality, while no specific risk factors were identified for relapse or NRM.
Relapse continued to be the most common cause of death in the subgroup of 1-year progression-free survivors (55% in low SES and 62% in high SES patients). Second malignancy (15 vs 15%), organ failure (8 vs 9%) and infections (5 vs 2%) were the less common causes of death following relapse.
DISCUSSION
We demonstrate the association between SES and outcomes of AHCT for lymphoma and show that patients from areas of low median income have lower OS after AHCT, including patients who have survived without evidence of disease progression for 1 year after transplantation. This finding is similar to results of other studies that investigated the role of SES in patients with lymphoma who have not undergone AHCT. 4, [23] [24] [25] [26] Relapse appeared to be the major driver of mortality in our main analysis that included all patients post AHCT. Disease status was noted to be a significant covariate for relapse and relapse mortality as well. Nikonova et al. 27 have shown that lower income status was associated with delay in diagnosis to treatment in diffuse large B-cell lymphoma, although this did not lead to a difference in survival. It can be hypothesized that low SES might be associated with worse disease status at AHCT, which later leads to the worse relapse mortality, although in our analysis, the association of SES with OS, PFS, relapse mortality and relapse was maintained even after adjusting for lymphoma subtype and disease status.
For patients who survived without disease progression for at least 1 year, the association with SES and OS was again observed, although this seemed to be mediated more by a trend toward increased risks of NRM than relapse. We acknowledge the relatively small sample size of this cohort, which limits any definitive conclusions. Although the choice of 1-year cutpoint was arbitrary, it represents a time point beyond which follow-up is primarily directed by non-transplant providers and close attention needs to be paid to screening and prevention of late effects of transplantation. 28 While more evidence accumulates, we highlight the need for particular attention to the long-term follow-up needs of an underserved population with low SES. Transplant center clinicians with experience in assessing socioeconomic issues can identify patients at high risk for financial toxicity in the early pretransplant period and then assist them in obtaining resources and grants to alleviate it during the pre-, peri-and post-transplant period. Patients at risk may also benefit from greater coordination of care and frequent communication between the transplant center and their referring and primary care physicians.
In this study, there was no significant impact of race on AHCT outcomes. The impact of other sociodemographic factors like race was controversial in previous studies that focused on patients not treated with AHCT.
4,23 Also, we observed that patients with low SES were more likely to live farther away from our transplant center. However, distance to transplant center did not impact outcomes.
Mitchell and Conklin 29 have recently looked at the utilization and outcomes of HCT for leukemia and lymphoma using California inpatient discharge and vital statistics death records. They showed that having private insurance and residence in a well-educated county increased the chances that a patient with leukemia or lymphoma underwent transplantation, while increasing age and distance to the nearest transplant hospital had the opposite effect. Among lymphoma patients, receipt of transplantation was associated with better survival, while uninsured patients and patients covered by state Medicaid or Medicare programs had higher probability of death. They did not see any influence of race/ ethnicity on survival. Their findings support our hypothesis that low SES, as a surrogate for other sociodemographic factors including insurance coverage, can mediate AHCT outcomes for lymphoma patients. Some limitations of our study have to be considered. We present a single institution retrospective cohort study, and our experience may not be representative. SES was assessed based on Abbreviations: CI = confidence interval; HR = hazard ratio; SES = socioeconomic status (adjusted for race, gender, age at transplant, diagnosis, disease status and number of prior chemotherapy regimens). Census tract data and was not patient self-reported, although using median annual household income based on ZIP Code of residence is a well-validated method in health services research. Our population was rather heterogeneous with an admixture of several lymphoma subtypes. We can only comment on patients who were able to receive transplantation and were not able to address the issue of access to transplantation. The results of our study are specific to the US and may not be applicable to the countries with different systems of health-care delivery, payment and infrastructure. However, we highlight a patient-specific issue that may apply to other countries and offer methods that transplant centers can apply for exploring SES disparities. Our results highlight low SES patients with lymphoma as a highrisk population that may need additional support through AHCT. Larger scale studies will further identify the high-risk population based on socioeconomic and sociodemographic factors for AHCTs in the future. Furthermore, future studies on this topic can guide practice in transplant centers and provide opportunities to improve on public health policy making for health-care equity in AHCT. Our study also highlights the need for active interventions to mitigate health-care disparities in this high-risk population. 
